TABLE 2.
Causes of death (intent‐to‐treat populations)
|
Median follow‐up 95% CI |
H34 low risk 7.6 y 6.5‐8.6 |
EORTC20012 7.7 y 7.1‐8.0 |
HD2000 10 y 9.3‐10.3 |
IIL 5.1 y 4.7‐5.2 |
All four studies 7 y 6.6‐7.2 |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABVD (N = 77) | BEACOPP (N = 68) | ABVD (N = 272) | BEACOPP (N = 269) | ABVD (N = 107) | BEACOPP (N = 89) | ABVD (N = 168) | BEACOPP (N = 163) | ABVD (N = 624) | BEACOPP (N = 589) | Total (N = 1213) | ||
| Death, n (%) | ||||||||||||
| No | 67 (87.0) | 67 (98.5) | 225 (82.7) | 226 (84.0) | 93 (86.9) | 75 (84.3) | 146 (86.9) | 148 (90.8) | 531 (85.1) | 516 (87.6) | 1047 (86.3) | |
| Yes | 10 (13.0) | 1 (1.5) | 47 (17.3) | 43 (16.0) | 14 (13.1) | 14 (15.7) | 22 (13.1) | 15 (9.2) | 93 (14.9) | 73 (12.4) | 166 (13.7) | |
| Cause, n (n of deaths < 18 mo) | n (% of all deaths) | |||||||||||
| HL | 5 (0) | 0 (0) | 20 (3) | 11 (4) | 13 (1) | 4 (2) | 19 (9) | 6 (1) | 57 (61.3) | 21 (28.8) | 78 (47.0) | |
| Treatment toxicity | 1 (0) | 0 (0) | 11 (6) | 7 (6) | 0 (0) | 1 (0) | 2 (1) | 8 (6) | 14 (15.0) | 16 (21.9) | 30 (18.1) | |
| ASCT toxicity | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) | 0 (0.0) | 1 0.6) | |
| Second cancer | 3 (0) | 1 (1) | 4 (0) | 15 (1) | 0 (0) | 5 (0) | 1 (0) | 1 (0) | 8 (8.6) | 22 (30.1) | 30 (18.1) | |
| MDS/AML | 0 (0) | 0 (0) | 0 (0) | 8 (0) | 0 (0) | 1 (0) | 0 (0) | 1 (0) | 0 | 10 | 10 | |
| Other cancers | 3 (0) | 1(1) | 4 (0) | 7 (1) | 0 (0) | 4 (0) | 1 (0) | 0 (0) | 8 | 12 | 20 | |
| Infection | 0 (0) | 0 (0) | 2 (2) | 3 (2) | 0 (0) | 4 (4) | 0 (0) | 0 (0) | 2 (2.1) | 7 (9.6) | 9 (5.4) | |
| Cardiovascular | 0 (0) | 0 (0) | 3 (1) | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (3.2) | 1 (1.4) | 4 (2.4) | |
| Other/unknown | 1 (0) | 0 (0) | 7 (1) | 6 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 8 (8.6) | 6 (8.2) | 14 (8.4) | |
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; AML, acute myeloid leukemia; ASCT, autologous stem cell transplantation; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome.